ABO non‐O type as a risk factor for thrombosis in patients with pancreatic cancer

Abstract

ABO blood type has previously been identified as a risk factor for thrombosis and pancreatic cancer (PC). The aim of the study is to demonstrate the associations between ABO blood type and other clinical factors with the risk of thromboembolism (TE) in patients with PC. We conducted a retrospective study in 670 patients with pathologically confirmed pancreatic adenocarcinoma at the University of Texas MD Anderson Cancer Center. Clinical information was retrieved from medical records. ABO blood type was determined serologically and/or genetically. Logistic regression models, Kaplan–Meier plot, log-rank test, and Cox proportional hazard regression models were employed in data analysis. The incidence of TE was 35.2% in 670 patients who did not have TE prior to cancer diagnosis. Pulmonary embolism (PE) and deep vein thrombosis (DVT) consisted 44.1% of the TE events. Non-O blood type, pancreatic body/tail tumors, previous use of antithrombotic medication, and obesity (body mass index >30 kg/m2) were significant predictors for TE in general. Blood type A and AB, low hemoglobin level (≤10 g/dL), obesity, metastatic tumor, and pancreatic body/tail tumors were significant predictors for PE and DVT. Patients with metastatic tumor or pancreatic body/tail tumors had a much higher frequency of early TE events (≤3 months after cancer diagnosis); and early TE occurrence was a significant independent predictor for increased risk of death. These observations suggest that ABO non-O blood type is an independent predictor for TE in PC. A better understanding of the risk factors for TE in PC may help to identify patients who are most likely to benefit from prophylactic anticoagulation therapy.

ABO blood types associated with the risk of venous thromboembolism in Han Chinese people: A hospital-based study of 200,000 patients

“…It is already known that ABO blood types are associated with the risk of VTE not only in unprovoked cases12, but also in provoked cases, such as cancer1314, pregnancy15, trauma16 or post-surgery1718. Meta-analysis showed that the prevalence of non-O blood types is higher in unprovoked VTE cases (OR = 1.88) than in provoked cases (OR = 1.33)3.…”

Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event

“…This 5-SNP score performed similarly to the score of all 31 SNPs, 20 and detected subjects at increased risk of both incident and recurrent VTE. [20][21][22] Genetic alterations such as Factor V Leiden, 23,24 ABO rs505922 and rs8176746, 25 ABO rs8176719, 26 and prothrombin G20210A [27][28][29][30] have all been found to be associated with VTE risk in cancer.…”

Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation

“…Adult studies have identified non‐O blood group as a risk factor for venous TE and that inherited thrombophilia increases the risk conferred by non‐O blood group . A meta‐analyses of 38 studies showed that non‐O blood group was the most common genetic prothrombotic risk factor especially in combination with FVL .…”